News Conference News HFSA 2025 Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM Yael L. Maxwell October 01, 2025
News Conference News HFSA 2025 Voice Analysis Picks Up Patients at Risk for HF Hospitalization: COMMUNITY-HF Yael L. Maxwell September 29, 2025
News Conference News HFSA 2024 Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM L.A. McKeown October 04, 2024
News Conference News HFSA 2024 Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity Todd Neale October 01, 2024
News Conference News HFSA 2023 STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization L.A. McKeown October 18, 2023
News Conference News HFSA 2023 ANTHEM-HFrEF Fails to Show Benefit of Vagal Nerve Stimulation Over GDMT Yael L. Maxwell October 16, 2023
News Conference News HFSA 2023 PA Pressure Monitoring Benefits HF Patients With No Recent Hospitalization L.A. McKeown October 12, 2023
News Conference News HFSA 2022 New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented Todd Neale October 07, 2022
News Conference News HFSA 2020 Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study L.A. McKeown October 12, 2020
News Conference News HFSA 2020 EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes L.A. McKeown October 09, 2020
News Conference News HFSA 2019 Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention L.A. McKeown September 24, 2019